Reposted by Clement Tsui PhD 🇭🇰 🇨🇦
Scientists find S. cerevisiae can help reduce vulvovaginal candidiasis severity by modulating fungal virulence and immune response, impacting millions globally. PMID:42362572, Nat Commun 2026, @NatureComms doi.org/10.1038/s41467-026-74733-2 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
doi.org
Saccharomyces cerevisiae reduces vulvovaginal candidiasis severity through modulation of fungal pathogenicity and inflammatory responses | Nature Communications
Vulvovaginal candidiasis (VVC) affects millions of women globally and is characterized by multifactorial immunopathology, with Candida albicans virulence driving disease progression through epithelial tissue damage and neutrophil hyperactivation and dysfunction contributing to disease severity. Here, we explored the multifaceted nature of S. cerevisiae as a live-biotherapeutic to attenuate C. albicans virulence and modulate host immune responses during VVC. We identified an S. cerevisiae isolate (Sc3458) that targets multiple aspects of C. albicans virulence, including fungal proliferation, adhesion, and hyphal morphogenesis, collectively impairing biofilm formation and disrupting pathogenic potential. These effects were linked to transcriptional reprogramming in C. albicans, marked by metabolic stress and downregulation of virulence- and biofilm-related genes. Additionally, S. cerevisiae (Sc3458) reduced inflammatory responses and neutrophil hyperactivation, while preserving neutrophi